ClinicalTrials.gg
CompletedNCT02423343Updated Sep 9, 2021Results posted

A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma

A Phase 1/2 interventional study of Galunisertib and Nivolumab in Solid Tumor, Non-Small Cell Lung Cancer Recurrent and Hepatocellular Carcinoma Recurrent, sponsored by Eli Lilly and Company. Completed at 9 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-09-09.

Sponsored by Eli Lilly and Company · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Jan 2015, registered Apr 2015).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
41
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 13 studies in Carcinoma, Hepatocellular by Eli Lilly and Company — none open to participants now, none under way, none of them phase 3. Carcinoma, Hepatocellular · Eli Lilly and Company.

Enrollment
9th of 13
41 · median 47
Started
2015
with 1 other
Phase 1/2
3 of 13
none open now
Registered
9th of 13
by date

Among the 13 studies in Carcinoma, Hepatocellular by Eli Lilly and Company, this one is the 9th largest by enrollment, is one of 2 that started in 2015, is one of 3 in phase 1/2, and was the 9th registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,062 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

None of the 13 studies in Carcinoma, Hepatocellular by Eli Lilly and Company is open now. The open studies under Carcinoma, Hepatocellular, anywhere →

Who these studies take

Of the 737 Carcinoma, Hepatocellular studies recruiting now, 382 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies in Carcinoma, Hepatocellular by Eli Lilly and Company as a file.
02

Study summary

The main purpose of this study is to evaluate the safety, tolerability, and efficacy of the study drug known as galunisertib in combination with nivolumab in participants with advanced refractory solid tumors and in recurrent or refractory non-small cell lung cancer (NSCLC) or hepatocellular carcinoma (HCC).

03

Conditions studied

  • Solid Tumor
  • Non-Small Cell Lung Cancer Recurrent
  • Hepatocellular Carcinoma Recurrent
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • For Phase 1b, must have advanced solid tumors in any .
  • For Phase 2, must have one of the following tumor types: recurrent or refractory NSCLC (any histology), or HCC with elevated alpha-fetoprotein (AFP) ≥200 nanogram/milliliter (ng/mL).
  • For Phase 2 only, have had disease progression or be refractory or intolerant to 1 prior line of therapy (first line therapy) for recurrent or refractory for NSCLC or HCC and have refused currently approved second-line therapy. First line therapy is defined as therapy used to treat advanced disease. This may include multiple chemotherapeutic, targeted or immunotherapeutic agents with or without radiation therapy and/or surgery. Each subsequent line of therapy is preceded by disease progression. A switch of an agent within the same drug class (eg, cisplatinum to carboplatinum) within a regimen in order to manage toxicity does not define the start of a new line of therapy.
  • For NSCLC:

    • Prior lines of therapy must include a platinum-based therapy. agents used in combination with standard therapies are allowed. Participants who received platinum-based or adjuvant therapy and subsequently received platinum-based therapy as first-line therapy are eligible.
    • Participants who have completed neo-adjuvant or adjuvant therapy with a platinum doublet and have experienced disease recurrence within 6 months of completing the platinum doublet are eligible.
    • Tumors with driver mutations (epidermal growth factor receptor mutation positive or anaplastic lymphoma kinase fusion oncogene positive) treated with a tyrosine kinase inhibitor or crizotinib are eligible. For participants who have progressed on a tyrosine kinase inhibitor or crizotinib or are intolerant to this targeted therapy, that participant must receive platinum-based therapy prior to enrollment in this study. Documentation of such mutations must be available and entered into the electronic case report form (eCRF).
    • Maintenance or switch maintenance therapy after first-line chemotherapy will be considered part of the first-line regimen and is acceptable.

Participants who completed and progressed on a platinum-containing regimen as adjuvant, neoadjuvant, or part of a course of chemoradiation therapy given from locally advanced disease and developed recurrent (local or ) disease within the 6 months before screening would be counted as having received 1 prior platinum-containing regimen and therefore would not require re-treatment with a platinum-containing regimen for Stage IIIB, IV, or recurrent disease and are eligible. However, participants must have received at least 2 cycles of a platinum doublet based chemotherapy before discontinuation for toxicity. If participants received only one cycle of a platinum doublet and discontinue due to clear progression, that regimen should be counted as a prior line of therapy.

  • For HCC:

    • One prior line of therapy which must include sorafenib or participant must have progressed or been intolerant to sorafenib for participants not eligible for transarterial chemoembolization. Participants who had sorafenib for locally advanced disease or are intolerant to sorafenib are eligible. Participants may have had clinical progression only following sorafenib or local therapy.
    • Must have A only. Participants may have any viral status (, , or none).
    • Have a viral load \<100 international units/milliliter (IU/mL).
    • For hepatitis B participants, must be on a nucleoside analog reverse transcriptase inhibitor (lamivudine, telbivudine, adefovir, tenofovir, or entecavir).
  • Have adequate organ function.
  • Have a performance status of 0 or 1 on the (ECOG) scale.
  • Use an approved method.

Exclusion criteria

Exclusion Criteria:

  • For Phase 2 only, more than 1 for their tumor type.
  • Have moderate or severe cardiovascular disease:

    • Have the presence of cardiac disease, including a myocardial infarction within 6 months prior to study entry, unstable angina pectoris, Class III/IV congestive heart failure, or uncontrolled hypertension.
    • Have documented major (ECG) abnormalities which are at the investigator's discretion (for example, symptomatic or sustained atrial or ventricular arrhythmias, second- or third-degree atrioventricular block, bundle-branch blocks, ventricular hypertrophy, or recent myocardial infarction).
    • Have major abnormalities documented by ECHO with Doppler:
    • Moderate or severe heart valve function defect including moderate or severe valve stenosis or regurgitation.
    • Left ventricular (LV) \<50%, evaluation based on the institutional lower limit of normal.
    • Have septal aneurysm or other heart aneurysm.
    • Any aneurysm of the major vessels.
  • Active infection with virus (HBV) (positive hepatitis B surface antigen); is allowed only in HCC participants. HCC participants at risk for HBV reactivation (as defined by anti-hepatitis B core antibody positive) are only eligible in the HCC cohort.
  • Have evidence of interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity or active, noninfectious pneumonitis.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    Galunisertib + Nivolumab (Cohort 1) Phase 1b

    50 milligrams (mg) Galunisertib administered orally once daily (QD) on Day 1 through Day 14 of each 4-week cycle in combination with 3 milligrams per kilogram (3 mg/kg) nivolumab given intravenously (IV), every 2 weeks (Q2W), (Day 1 and Day 15). Participants may continue to receive study drug until discontinuation criteria are met.

    Drug: Galunisertib · Drug: Nivolumab

  • Experimental
    Galunisertib + Nivolumab (Cohort 2) Phase 1b

    50 mg Galunisertib administered orally twice daily (BID) on Day 1 through Day 14 of each 4-week cycle in combination with 3 mg/kg nivolumab given IV, Q2W,(Day 1 and Day 15). Participants may continue to receive study drug until discontinuation criteria are met.

    Drug: Galunisertib · Drug: Nivolumab

  • Experimental
    Galunisertib + Nivolumab (Cohort 3) Phase 1b

    80 mg Galunisertib administered orally BID on Day 1 through Day 14 of each 4-week cycle in combination with 3 mg/kg nivolumab given IV, Q2W, (Day 1 and Day 15). Participants may continue to receive study drug until discontinuation criteria are met.

    Drug: Galunisertib · Drug: Nivolumab

  • Experimental
    Galunisertib + Nivolumab (Cohort 4) Phase 1b

    150 mg Galunisertib administered orally BID on Day 1 through Day 14 of each 4-week cycle in combination with 3 mg/kg nivolumab given IV, Q2W,(Day 1 and Day 15). Participants may continue to receive study drug until discontinuation criteria are met.

    Drug: Galunisertib · Drug: Nivolumab

  • Experimental
    Galunisertib + Nivolumab - Non-small Cell Lung Cancer (NSCLC) Phase 2

    150 mg Galunisertib administered orally BID for the first 14 days of each 4-week cycle in combination with 3 mg/kg nivolumab given IV, Q2W, (Day 1 and Day 15) of each 4-week cycle. Participants may continue to receive study drug until discontinuation criteria are met.

    Drug: Galunisertib · Drug: Nivolumab

  • Experimental
    Galunisertib + Nivolumab - Hepatocellular Carcinoma (HCC) Phase 2

    150 mg Galunisertib administered orally BID for the first 14 days of each 4-week cycle in combination with 3 mg/kg nivolumab given IV, Q2W, (Day 1 and Day 15) of each 4-week cycle. Participants may continue to receive study drug until discontinuation criteria are met.

    Drug: Galunisertib · Drug: Nivolumab

Interventions

  • Administered orally

    Also known as: LY2157299

  • Administered IV

    Also known as: OPDIVO®

06

What researchers measure

Primary outcomes

  1. Phase 1b: Maximum Tolerated Dose (MTD) of Galunisertib in Combination With Nivolumab

    The MTD is defined as the highest tested dose that has less than 33% probability of causing a dose limiting toxicity (DLT).

    Time frame: Cycle 1 through Cycle 2 (Up to 2 Months)

Secondary outcomes

  1. Pharmacokinetics (PK): Minimum Concentration (Cmin) of Nivolumab

    Minimum Concentration (Cmin) of Nivolumab

    Time frame: PK: Cycle 1 Day 15 Predose; Cycle 2: Day 1: Pre-dose; Day 15: Predose: Cycle 4: Day 1: Predose

  2. PK: Area Under the Plasma Concentration -Time Curve of Galunisertib From Time Zero to 24 Hours (AUC [0-24h]) at Steady State

    Area under the plasma concentration curve from time zero to 24 hours of galunisertib for Cycle 1 and Cycle 2.

    Time frame: PK: Cycle 1 and Cycle 2 Day 1: Predose, 0.5 - 3 hours postdose, Cycle 1 and Cycle 2 Day 14: Predose, 0.5 - 2, 3.5 - 5, and 24 hours postdose through Cycle 4 Day 1 predose

  3. Number of Participants With Anti-Nivolumab Antibodies When Administered in Combination With Galunisertib

    Participants with treatment-emergent anti-nivolumab antibodies when administered with galunisertib were participants with a 4-fold or greater increase in titer from baseline measurement (treatment-boosted). If baseline result is ADA not present, then the subject is TE ADA+, if there is at least 1 postbaseline result of ADA present with titer ≥ 40 (treatment-induced).

    Time frame: Cycle 1: Days 1, 14, 15 Predose and Day 100 Follow-up; Cycles 2 and 4: Day 1 Predose and Day 100 Follow-up

  4. Phase 2: Progression Free Survival (PFS)

    PFS was defined as the time from the date of first study treatment to the first evidence of disease progression as defined by response evaluation criteria in solid tumors (RECIST) v1.1 or death from any cause. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. If a participant does not have a complete baseline disease assessment, then the PFS time was censored at the date of randomization, regardless of whether or not objectively determined disease progression or death has been observed for the participant. If a participant was not known to have died or have objective progression as of the data inclusion cutoff date for the analysis, the PFS time was censored at the last adequate tumor assessment date.

    Time frame: Date of First Study Treatment to Measured Progressive Disease or Death (Up to 35 Months)

  5. Phase 2: Percentage of Participants Who Achieve Best Overall Tumor Response of Complete Response or Partial Response: Objective Response Rate (ORR)

    Objective Response Rate was the percentage of participants achieving a best overall response (BOR) of complete response (CR) or partial response (PR) as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. PD was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. Overall response rate is calculated as a total number of participants with CR or PR divided by the total number of participants with at least 1 measurable lesion, multiplied by 100.

    Time frame: Baseline to Measured Progressive Disease (Up to 35 Months)

  6. Phase 2: Duration of Response (DoR)

    Duration of response was measured from the date of documented response to the date of first progression of disease or the date of death due to any cause, whichever is earlier.

    Time frame: Date of Complete Response (CR) or Partial Response (PR) to Date of Objective Disease Progression or Death Due to Any Cause (Up to 35 Months)

  7. Phase 2: Time to Response

    Time to response was measured from the date of first study treatment to the first documented response of Complete Response (CR) or Partial Response (PR).

    Time frame: Date of First Study Treatment to Date of Complete Response or Partial Response (Up to 35 Months)

  8. Phase 2: Overall Survival (OS)

    Overall Survival was determined from the date of first study treatment until death due to any cause.

    Time frame: Date of First Study Treatment to Death from Any Cause (Up to 35 Months)

07

Results

Posted Sep 9, 2021
Limitations and caveats
Due low enrollment, the HCC cohort was terminated early.

Participant flow

Due low enrollment, the Hepatocellular Carcinoma (HCC) cohort was terminated early.

Participant flow — Overall Study
MilestoneGalunisertib + Nivolumab (Cohort 1) Phase 1bGalunisertib + Nivolumab (Cohort 2) Phase 1bGalunisertib + Nivolumab (Cohort 3) Phase 1bGalunisertib + Nivolumab (Cohort 4) Phase 1bGalunisertib + Nivolumab - Non-Small Cell Lung Cancer (NSCLC) Phase 2Galunisertib + Nivolumab - Hepatocellular Carcinoma (HCC) Phase 2
Started3534251
Received at least one dose of study drug3534251
Completed3434201
Not completed010050
Withdrew: Withdrawal by subject010000
Withdrew: Progressive disease000020
Withdrew: Adverse event000020
Withdrew: Death000010

Outcome measures

PrimaryPhase 1b: Maximum Tolerated Dose (MTD) of Galunisertib in Combination With Nivolumab

The MTD is defined as the highest tested dose that has less than 33% probability of causing a dose limiting toxicity (DLT).

Time frame:
Cycle 1 through Cycle 2 (Up to 2 Months)
Reported as:
Number · milligrams (mg)
Phase 1b: Maximum Tolerated Dose (MTD) of Galunisertib in Combination With Nivolumab
milligrams (mg)Phase 1b Participants
Phase 1b: Maximum Tolerated Dose (MTD) of Galunisertib in Combination With Nivolumab300
SecondaryPharmacokinetics (PK): Minimum Concentration (Cmin) of Nivolumab

Minimum Concentration (Cmin) of Nivolumab

Time frame:
PK: Cycle 1 Day 15 Predose; Cycle 2: Day 1: Pre-dose; Day 15: Predose: Cycle 4: Day 1: Predose
Reported as:
Mean · micrograms per milliliter (µg/mL)
Pharmacokinetics (PK): Minimum Concentration (Cmin) of Nivolumab
micrograms per milliliter (µg/mL)Galunisertib + Nivolumab (Cohort 1) Phase 1bGalunisertib + Nivolumab (Cohort 2) Phase 1bGalunisertib + Nivolumab (Cohort 3) Phase 1bGalunisertib + Nivolumab (Cohort 4) Phase 1bGalunisertib + Nivolumab (NSCLC) Phase 2Galunisertib + Nivolumab ( HCC) Phase 2
Pharmacokinetics (PK): Minimum Concentration (Cmin) of Nivolumab33.5 (19.9 to 53.6)36.2 (11.8 to 58.1)43.2 (5.45 to 76)29.2 (9.39 to 63.7)37.6 (1.08 to 105)—
SecondaryPK: Area Under the Plasma Concentration -Time Curve of Galunisertib From Time Zero to 24 Hours (AUC [0-24h]) at Steady State

Area under the plasma concentration curve from time zero to 24 hours of galunisertib for Cycle 1 and Cycle 2.

Time frame:
PK: Cycle 1 and Cycle 2 Day 1: Predose, 0.5 - 3 hours postdose, Cycle 1 and Cycle 2 Day 14: Predose, 0.5 - 2, 3.5 - 5, and 24 hours postdose through Cycle 4 Day 1 predose
Reported as:
Geometric mean · micrograms*hour per liter (μg*h/L)
PK: Area Under the Plasma Concentration -Time Curve of Galunisertib From Time Zero to 24 Hours (AUC [0-24h]) at Steady State
micrograms*hour per liter (μg*h/L)Galunisertib + Nivolumab (Cohort 1) Phase 1bGalunisertib + Nivolumab (Cohort 2) Phase 1bGalunisertib + Nivolumab (Cohort 3) Phase 1bGalunisertib + Nivolumab (Cohort 4) Phase 1bGalunisertib + Nivolumab (NSCLC ) Phase 2Galunisertib + Nivolumab ( HCC) Phase 2
PK: Area Under the Plasma Concentration -Time Curve of Galunisertib From Time Zero to 24 Hours (AUC [0-24h]) at Steady State3060 ± 412350 ± 462220 ± 1645580 ± 617322 ± 67NA ± NA
SecondaryNumber of Participants With Anti-Nivolumab Antibodies When Administered in Combination With Galunisertib

Participants with treatment-emergent anti-nivolumab antibodies when administered with galunisertib were participants with a 4-fold or greater increase in titer from baseline measurement (treatment-boosted). If baseline result is ADA not present, then the subject is TE ADA+, if there is at least 1 postbaseline result of ADA present with titer ≥ 40 (treatment-induced).

Time frame:
Cycle 1: Days 1, 14, 15 Predose and Day 100 Follow-up; Cycles 2 and 4: Day 1 Predose and Day 100 Follow-up
Reported as:
Count of participants · Participants
Number of Participants With Anti-Nivolumab Antibodies When Administered in Combination With Galunisertib
ParticipantsGalunisertib + Nivolumab (Cohort 1) Phase 1bGalunisertib + Nivolumab (Cohort 2) Phase 1bGalunisertib + Nivolumab (Cohort 3) Phase 1bGalunisertib + Nivolumab (Cohort 4) Phase 1bGalunisertib + Nivolumab (NSCLC) Phase 2Galunisertib + Nivolumab (HCC) Phase 2
Number of Participants With Anti-Nivolumab Antibodies When Administered in Combination With Galunisertib000000
SecondaryPhase 2: Progression Free Survival (PFS)

PFS was defined as the time from the date of first study treatment to the first evidence of disease progression as defined by response evaluation criteria in solid tumors (RECIST) v1.1 or death from any cause. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. If a participant does not have a complete baseline disease assessment, then the PFS time was censored at the date of randomization, regardless of whether or not objectively determined disease progression or death has been observed for the participant. If a participant was not known to have died or have objective progression as of the data inclusion cutoff date for the analysis, the PFS time was censored at the last adequate tumor assessment date.

Time frame:
Date of First Study Treatment to Measured Progressive Disease or Death (Up to 35 Months)
Reported as:
Median · months
Phase 2: Progression Free Survival (PFS)
monthsGalunisertib + Nivolumab (NSCLC) Phase 2Galunisertib + Nivolumab (HCC) Phase 2
Phase 2: Progression Free Survival (PFS)5.26 (1.77 to 9.20)5.39
SecondaryPhase 2: Percentage of Participants Who Achieve Best Overall Tumor Response of Complete Response or Partial Response: Objective Response Rate (ORR)

Objective Response Rate was the percentage of participants achieving a best overall response (BOR) of complete response (CR) or partial response (PR) as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. PD was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. Overall response rate is calculated as a total number of participants with CR or PR divided by the total number of participants with at least 1 measurable lesion, multiplied by 100.

Time frame:
Baseline to Measured Progressive Disease (Up to 35 Months)
Reported as:
Number · Percentage of Participants
Phase 2: Percentage of Participants Who Achieve Best Overall Tumor Response of Complete Response or Partial Response: Objective Response Rate (ORR)
Percentage of ParticipantsGalunisertib + Nivolumab (NSCLC) Phase 2Galunisertib + Nivolumab (HCC) Phase 2
Phase 2: Percentage of Participants Who Achieve Best Overall Tumor Response of Complete Response or Partial Response: Objective Response Rate (ORR)24.00
SecondaryPhase 2: Duration of Response (DoR)

Duration of response was measured from the date of documented response to the date of first progression of disease or the date of death due to any cause, whichever is earlier.

Time frame:
Date of Complete Response (CR) or Partial Response (PR) to Date of Objective Disease Progression or Death Due to Any Cause (Up to 35 Months)
Reported as:
Median · months
Phase 2: Duration of Response (DoR)
monthsGalunisertib + Nivolumab (NSCLC) Phase 2Galunisertib + Nivolumab (HCC) Phase 2
Phase 2: Duration of Response (DoR)9.03 (1.97 to 35)—
SecondaryPhase 2: Time to Response

Time to response was measured from the date of first study treatment to the first documented response of Complete Response (CR) or Partial Response (PR).

Time frame:
Date of First Study Treatment to Date of Complete Response or Partial Response (Up to 35 Months)
Reported as:
Median · months
Phase 2: Time to Response
monthsGalunisertib + Nivolumab (NSCLC) Phase 2Galunisertib + Nivolumab (HCC) Phase 2
Phase 2: Time to Response4.2 (0.5 to 35)—
SecondaryPhase 2: Overall Survival (OS)

Overall Survival was determined from the date of first study treatment until death due to any cause.

Time frame:
Date of First Study Treatment to Death from Any Cause (Up to 35 Months)
Reported as:
Median · months
Phase 2: Overall Survival (OS)
monthsGalunisertib + Nivolumab (NSCLC) Phase 2Galunisertib + Nivolumab (HCC) Phase 2
Phase 2: Overall Survival (OS)11.99 (8.15 to 16.23)14.52

Adverse events

Collected over Up to 35 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Galunisertib + Nivolumab (Cohort 1) Phase 1b2/3 (66.7%)1/3 (33.3%)3/3 (100%)
Galunisertib + Nivolumab (Cohort 2) Phase 1b4/5 (80%)2/5 (40%)4/5 (80%)
Galunisertib + Nivolumab (Cohort 3) Phase 1b1/3 (33.3%)1/3 (33.3%)3/3 (100%)
Galunisertib + Nivolumab (Cohort 4) Phase 1b3/4 (75%)2/4 (50%)4/4 (100%)
Galunisertib + Nivolumab (NSCLC) Phase 217/25 (68%)13/25 (52%)23/25 (92%)
Galunisertib + Nivolumab (HCC) Phase 21/1 (100%)0/1 (0%)1/1 (100%)
Most frequent serious events
Showing 10 of 29
Most frequent serious events
EventGalunisertib + Nivolumab (Cohort 1) Phase 1bGalunisertib + Nivolumab (Cohort 2) Phase 1bGalunisertib + Nivolumab (Cohort 3) Phase 1bGalunisertib + Nivolumab (Cohort 4) Phase 1bGalunisertib + Nivolumab (NSCLC) Phase 2Galunisertib + Nivolumab (HCC) Phase 2
DyspepsiaGastrointestinal disorders0/30/51/30/40/250/1
Large intestinal obstructionGastrointestinal disorders0/30/51/30/40/250/1
VomitingGastrointestinal disorders1/30/50/30/40/250/1
PyelonephritisInfections and infestations0/30/51/30/40/250/1
DehydrationMetabolism and nutrition disorders0/30/51/30/40/250/1
Pain in extremityMusculoskeletal and connective tissue disorders1/30/50/30/40/250/1
HydronephrosisRenal and urinary disorders0/30/51/30/40/250/1
CoughRespiratory, thoracic and mediastinal disorders1/30/50/30/40/250/1
DyspnoeaRespiratory, thoracic and mediastinal disorders1/30/50/30/42/250/1
Small intestinal obstructionGastrointestinal disorders0/30/50/31/40/250/1
Most frequent other events
Showing 10 of 140
Most frequent other events
EventGalunisertib + Nivolumab (Cohort 1) Phase 1bGalunisertib + Nivolumab (Cohort 2) Phase 1bGalunisertib + Nivolumab (Cohort 3) Phase 1bGalunisertib + Nivolumab (Cohort 4) Phase 1bGalunisertib + Nivolumab (NSCLC) Phase 2Galunisertib + Nivolumab (HCC) Phase 2
GingivitisInfections and infestations0/30/50/30/40/251/1
RhinorrhoeaRespiratory, thoracic and mediastinal disorders0/30/50/30/40/251/1
Amylase increasedInvestigations0/30/50/33/42/250/1
VomitingGastrointestinal disorders2/30/51/30/43/250/1
NauseaGastrointestinal disorders1/31/51/32/46/250/1
Non-cardiac chest painGeneral disorders0/30/50/32/41/250/1
Aspartate aminotransferase increasedInvestigations0/30/50/32/42/250/1
Blood alkaline phosphatase increasedInvestigations0/30/50/32/41/250/1
Gamma-glutamyltransferase increasedInvestigations0/30/50/32/42/250/1
Lipase increasedInvestigations0/30/50/32/41/250/1

Baseline characteristics

All participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)Galunisertib + Nivolumab (Cohort 1) Phase 1bGalunisertib + Nivolumab (Cohort 2) Phase 1bGalunisertib + Nivolumab (Cohort 3) Phase 1bGalunisertib + Nivolumab (Cohort 4) Phase 1bGalunisertib + Nivolumab - Non Small Cell Lung Cancer (NSCLC) Phase 2Galunisertib + Nivolumab - Hepatocellular Carcinoma(HCC) Phase 2Total
Mean60.7 ± 15.647.2 ± 15.836.0 ± 5.361.5 ± 9.061.0 ± 8.464.0 ± NA57.6 ± 12.1
Sex: Female, Male
Sex: Female, Male(Participants)Galunisertib + Nivolumab (Cohort 1) Phase 1bGalunisertib + Nivolumab (Cohort 2) Phase 1bGalunisertib + Nivolumab (Cohort 3) Phase 1bGalunisertib + Nivolumab (Cohort 4) Phase 1bGalunisertib + Nivolumab - Non Small Cell Lung Cancer (NSCLC) Phase 2Galunisertib + Nivolumab - Hepatocellular Carcinoma(HCC) Phase 2Total
Female11139116
Male242116025
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Galunisertib + Nivolumab (Cohort 1) Phase 1bGalunisertib + Nivolumab (Cohort 2) Phase 1bGalunisertib + Nivolumab (Cohort 3) Phase 1bGalunisertib + Nivolumab (Cohort 4) Phase 1bGalunisertib + Nivolumab - Non Small Cell Lung Cancer (NSCLC) Phase 2Galunisertib + Nivolumab - Hepatocellular Carcinoma(HCC) Phase 2Total
American Indian or Alaska Native0000000
Asian0000000
Native Hawaiian or Other Pacific Islander0000000
Black or African American1001002
White253325139
More than one race0000000
Unknown or Not Reported0000000
Region of Enrollment
Region of Enrollment(Participants)Galunisertib + Nivolumab (Cohort 1) Phase 1bGalunisertib + Nivolumab (Cohort 2) Phase 1bGalunisertib + Nivolumab (Cohort 3) Phase 1bGalunisertib + Nivolumab (Cohort 4) Phase 1bGalunisertib + Nivolumab - Non Small Cell Lung Cancer (NSCLC) Phase 2Galunisertib + Nivolumab - Hepatocellular Carcinoma(HCC) Phase 2Total
United States33241013
Spain021024128
08

Study locations

9 sites
  • University of Alabama at Birmingham Medical Center
    Birmingham, Alabama 35294, United States
  • University of California - San Diego
    La Jolla, California 92093, United States
  • H Lee Moffitt Cancer Center
    Tampa, Florida 33612-9497, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Hospital Universitari Vall d'Hebron
    Barcelona, 08035, Spain
  • Institut Catala d'Oncologia
    Barcelona, 08907, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
  • Hospital Regional Universitario de Málaga
    Malaga, 29010, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2015 to primary completion in Dec 2018, 47 months.

Results were first posted in Sep 2021, 2 years 8 months after primary completion. A results delay was requested in Dec 2019.

Of 72 industry-sponsored phase 1/2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 74. This study's 47 months is close to that.

Counting every sponsor, half of 136 studies reached it within 53 months; a quarter within 38 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2015
First posted
Apr 22, 2015
StartActual
Jan 1, 2015
Primary completionActual
Dec 13, 2018
CompletionActual
Jul 8, 2020
Results delay requested
Dec 7, 2019
Results first posted
Sep 9, 2021
Last update
Sep 9, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02423343
Responsible party
Sponsor
First posted
Apr 22, 2015
Start date
Jan 1, 2015
Primary completion
Dec 13, 2018
Completion
Jul 8, 2020
Results posted
Sep 9, 2021
Last update
Sep 9, 2021

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: LY-2157299

Start the discussion